Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up - Report - MDSpire
Advertisement
Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up
Correction: Brentuximab Vedotin Plus Chemotherapy in Front-Line sALCL Treatment
Overview
This correction clarifies that the reported 5-year progression-free survival (PFS) rates pertain specifically to patients with ALK– systemic anaplastic large cell lymphoma (sALCL) who achieved a complete response (CR) following treatment. The estimated 5-year PFS rates were similar between the brentuximab vedotin plus CHP (A + CHP) and CHOP arms in this subgroup.
Background
Systemic anaplastic large cell lymphoma (sALCL) is a subtype of peripheral T-cell lymphoma characterized by the expression of anaplastic lymphoma kinase (ALK) in some cases. Treatment regimens combining brentuximab vedotin with chemotherapy (A + CHP) have been evaluated against standard CHOP chemotherapy in the ECHELON-2 study. Long-term follow-up data are critical to understanding the durability of responses and survival outcomes in these patients.
Data Highlights
In patients with ALK– sALCL who achieved complete response, the estimated 5-year progression-free survival (PFS) rates were 56.8% (95% CI: 40.5–70.2%) for the A + CHP arm and 56.0% (95% CI: 39.3–69.7%) for the CHOP arm. The original sentence was corrected to specify that these rates apply only to patients achieving CR, not all patients with ALK– disease.
Key Findings
The original article reported 5-year PFS rates for ALK– sALCL patients achieving complete response, not for all ALK– patients.
Estimated 5-year PFS was 56.8% in the A + CHP arm versus 56.0% in the CHOP arm among patients with ALK– sALCL who achieved CR.
The correction clarifies potential misinterpretation by explicitly stating the subgroup analyzed.
Data for 5-year PFS in all patients with ALK– disease, regardless of response, are presented separately in the original article's Figure 1.
This correction ensures accurate interpretation of long-term efficacy outcomes in the ECHELON-2 study subgroup analysis.
Clinical Implications
Clinicians should note that the reported 5-year PFS benefits of brentuximab vedotin plus chemotherapy apply specifically to patients with ALK– sALCL who achieve complete response. This distinction is important for treatment planning and prognostic counseling. Long-term follow-up data remain essential to guide therapeutic decisions in this patient population.
Conclusion
This correction refines the interpretation of long-term outcomes from the ECHELON-2 study, emphasizing that 5-year PFS rates reported pertain to ALK– sALCL patients achieving complete response. Accurate subgroup specification enhances clinical understanding of treatment efficacy.
by Eva Domingo-Domènech, Barbara Pro, Tim Illidge, Steven Horwitz, Lorenz Trumper, Swami Iyer, Ranjana Advani, Nancy L. Bartlett, Jacob Haaber Christensen, Won-Seog Kim, Tatyana Feldman, Ilseung Choi, Giuseppe Gritti, David Belada, Andrei Shustov, Arpad Illes, Pier Luigi Zinzani, Andreas Hüttmann, Marek Trneny, Steven Le Gouill, Deepa Jagadeesh, Jonathan W. Friedberg, Meredith Little, Cassie Dong, Michelle Fanale, Keenan Fenton, Kerry J. Savage
Dana-Farber Cancer Institute’s adult stem cell transplant program and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center’s pediatric stem cell transplant program have once again received exceptional ratings from the Center for International Blood & Marrow Transplant Research (CIBMTR), earning a +1 performance score, the highest possible designation, on their annual center-specific survival reports.
